Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

68Ga-PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Adenocarcinoma: PET Findings Correlate with Outcomes After Definitive Treatment

Farshad Moradi, Heying Duan, Hong Song, Guido A. Davidzon, Benjamin I. Chung, Alan E. C. Thong, Andreas M. Loening, Pejman Ghanouni, Geoffrey Sonn and Andrei Iagaru
Journal of Nuclear Medicine December 2022, 63 (12) 1822-1828; DOI: https://doi.org/10.2967/jnumed.122.263897
Farshad Moradi
1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heying Duan
1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Song
1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guido A. Davidzon
1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin I. Chung
2Department of Urology, Stanford University, Stanford, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan E. C. Thong
2Department of Urology, Stanford University, Stanford, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas M. Loening
3Division of Body MRI, Department of Radiology, Stanford University, Stanford, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pejman Ghanouni
3Division of Body MRI, Department of Radiology, Stanford University, Stanford, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey Sonn
2Department of Urology, Stanford University, Stanford, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrei Iagaru
1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Visual Abstract

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Abstract

Prostate-specific membrane antigen (PSMA) PET offers an accuracy superior to other imaging modalities in initial staging of prostate cancer and is more likely to affect management. We examined the prognostic value of 68Ga-PSMA-11 uptake in the primary lesion and presence of metastatic disease on PET in newly diagnosed prostate cancer patients before initial therapy. Methods: In a prospective study from April 2016 to December 2020, 68Ga-PSMA-11 PET/MRI was performed in men with a new diagnosis of intermediate- or high-grade prostate cancer who were candidates for prostatectomy. Patients were followed up after initial therapy for up to 5 y. We examined the Kendall correlation between PET (intense uptake in the primary lesion and presence of metastatic disease) and clinical and pathologic findings (grade group, extraprostatic extension, nodal involvement) relevant for risk stratification, and examined the relationship between PET findings and outcome using Kaplan–Meier analysis. Results: Seventy-three men (age, 64.0 ± 6.3 y) were imaged. Seventy-two had focal uptake in the prostate, and in 20 (27%) PSMA-avid metastatic disease was identified. Uptake correlated with grade group and prostate-specific antigen (PSA). Presence of PSMA metastasis correlated with grade group and pathologic nodal stage. PSMA PET had higher per-patient positivity than nodal dissection in patients with only 5–15 nodes removed (8/41 vs. 3/41) but lower positivity if more than 15 nodes were removed (13/21 vs. 10/21). High uptake in the primary lesion (SUVmax > 12.5, P = 0.008) and presence of PSMA metastasis (P = 0.013) were associated with biochemical failure, and corresponding hazard ratios for recurrence within 2 y (4.93 and 3.95, respectively) were similar to or higher than other clinicopathologic prognostic factors. Conclusion: 68Ga-PSMA-11 PET can risk-stratify patients with intermediate- or high-grade prostate cancer before prostatectomy based on degree of uptake in the prostate and presence of metastatic disease.

  • oncology: GU
  • PET
  • PET/MRI
  • prostate cancer
  • biochemical recurrence
  • prostate-specific membrane
  • antigen
  • prostatectomy

Footnotes

  • Published online May. 5, 2022.

  • © 2022 by the Society of Nuclear Medicine and Molecular Imaging.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (12)
Journal of Nuclear Medicine
Vol. 63, Issue 12
December 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
68Ga-PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Adenocarcinoma: PET Findings Correlate with Outcomes After Definitive Treatment
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
68Ga-PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Adenocarcinoma: PET Findings Correlate with Outcomes After Definitive Treatment
Farshad Moradi, Heying Duan, Hong Song, Guido A. Davidzon, Benjamin I. Chung, Alan E. C. Thong, Andreas M. Loening, Pejman Ghanouni, Geoffrey Sonn, Andrei Iagaru
Journal of Nuclear Medicine Dec 2022, 63 (12) 1822-1828; DOI: 10.2967/jnumed.122.263897

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
68Ga-PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Adenocarcinoma: PET Findings Correlate with Outcomes After Definitive Treatment
Farshad Moradi, Heying Duan, Hong Song, Guido A. Davidzon, Benjamin I. Chung, Alan E. C. Thong, Andreas M. Loening, Pejman Ghanouni, Geoffrey Sonn, Andrei Iagaru
Journal of Nuclear Medicine Dec 2022, 63 (12) 1822-1828; DOI: 10.2967/jnumed.122.263897
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study
  • 177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy
  • Adverse Clinical Events at the Injection Site Are Exceedingly Rare After Reported Radiopharmaceutical Extravasation in Patients Undergoing 99mTc-MDP Whole-Body Bone Scintigraphy: A 12-Year Experience
Show more Clinical Investigation

Similar Articles

Keywords

  • Oncology: GU
  • PET
  • PET/MRI
  • Prostate Cancer
  • biochemical recurrence
  • prostate-specific membrane
  • antigen
  • prostatectomy
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire